BioCryst Presents New Real-World Evidence Showing Reduction in Angioedema-Related Medical Visits After Switching to ORLADEYO® (Interotralstat) at ACAAI 2026 Annual Scientific Conference.
BioCryst Presents New Real-World Evidence Showing Reduction in Angioedema-Related Medical Visits After Switching to ORLADEYO® (Interotralstat) at ACAAI 2026 Annual Scientific Conference.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in